Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

This study has been terminated.
(The biological effect seen with natalizumab was not sufficient to warrant further development in RA.)
Elan Pharmaceuticals
Information provided by (Responsible Party):
Biogen Identifier:
First received: January 27, 2009
Last updated: June 14, 2016
Last verified: January 2009
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)